Desvenlafaxine Extended Release Tablets 100mg
Desvenlafaxine Tablet, Extended Release
Product Images NDC 68788-7175
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68788-7175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Desvenlafaxine Figure1)
This text describes the effects of hepatic and renal impairment, as well as age and gender, on the plasma concentrations of an unknown drug. The data suggests that renal impairment has a moderate effect on Cmax and a greater effect on AUC, with more severe impairment resulting in higher plasma concentrations. Hepatic impairment has a smaller effect, with moderate and severe impairment resulting in slightly higher Cmax and AUC values. The text includes population descriptions such as age and gender, as well as a footnote defining ESRD as end-stage renal disease.*
Figure 2 (Desvenlafaxine Figure2)
This is a pharmacokinetic data table showing changes in CYP3A4 inhibitors due to Ketoconazole. It includes the geometric mean ratio of the maximum concentration (Cmax) and area under the curve (AUC) of Ketoconazole with a confidence interval of 30%. The values in parentheses represent the upper and lower bounds of the confidence interval. The table also shows the change relative to the reference.*
Figure 3 (Desvenlafaxine Figure3)
Figure 4 (Desvenlafaxine Image4)
This appears to be a graph showing the estimated proportion of patients with relapse over time using Desvenlafaxine Extended-Release Tablets 50mg versus placebo. The X-axis indicates the time to relapse in days, while the Y-axis shows the estimated percentage of patients experiencing relapse. The graph suggests that Desvenlafaxine may be more effective than placebo in preventing relapse.*
Figure 5 (Desvenlafaxine Image5)
This appears to be a graph showing the estimated proportion of patients with relapse over time for Desvenlafaxine Extended-Release Tablets compared to placebo. The x-axis shows time to relapse in days from randomization and the y-axis shows the percentage of patients with relapse. The graph shows a higher percentage of relapse with placebo compared to Desvenlafaxine. The values on the y-axis range from 20% to 50%.*
Structure (Desvenlafaxine Structure1)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
